IDRAPARINUX

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C38H64O49S7
Molecular Weight	1529.34
Optical Activity	UNSPECIFIED
Defined Stereocenters	25 / 25
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3OS(O)(=O)=O)[C@H](OC)[C@H]2OC)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O

InChI

InChIKey=AJBMORBNKXNZSF-COSHMZDQSA-N

InChI=1S/C38H64O49S7/c1-64-15-12(9-72-88(43,44)45)76-35(27(68-5)18(15)65-2)80-21-19(66-3)28(69-6)37(82-25(21)32(39)40)79-17-14(11-74-90(49,50)51)77-38(31(87-94(61,62)63)24(17)85-92(55,56)57)81-22-20(67-4)29(70-7)36(83-26(22)33(41)42)78-16-13(10-73-89(46,47)48)75-34(71-8)30(86-93(58,59)60)23(16)84-91(52,53)54/h12-31,34-38H,9-11H2,1-8H3,(H,39,40)(H,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)/t12-,13-,14-,15-,16-,17-,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-,31-,34+,35-,36-,37-,38-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C38H64O49S7
Molecular Weight	1529.34
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	25 / 25
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18447601 | https://www.ncbi.nlm.nih.gov/pubmed/22111528

Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug.

Originator

Approval Year

PubMed

Title	Date	PubMed
Idraparinux and idrabiotaparinux.	2010-01	22111528
Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.	2008-05	18447601
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.	2008-01-26	18294998

Sample Use Guides

In Vivo Use Guide

The administration of idraparinux in subcutaneous fixed doses of 2.5 mg once weekly was found to be as effective and safe as conventional antithrombotic therapy in the initial treatment of patients with deep vein thrombosis, but less effective than standard therapy in the initial treatment of patients with primary pulmonary embolism

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:20:26 GMT 2025` Edited by `admin` on `Mon Mar 31 20:20:26 GMT 2025`
Record UNII	6ADD3H8MFZ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SR-34006

Preferred Name

English

IDRAPARINUX

Common Name

English

SR34006

Code

English

IDRAPARINUX [MI]

Common Name

English

Idraparinux [WHO-DD]

Common Name

English

Code System Code Type Description

WIKIPEDIA

IDRAPARINUX